A number of other research firms have also weighed in on NXGN. Cantor Fitzgerald boosted their target price on Nextgen Healthcare from $12.00 to $13.00 and gave the stock a “neutral” rating in a report on Friday. SVB Leerink assumed coverage on Nextgen Healthcare in a research note on Monday, April 13th. They issued a “market perform” rating and a $12.00 price target for the company. Piper Sandler upped their target price on Nextgen Healthcare from $17.00 to $23.00 and gave the company an “overweight” rating in a research report on Friday. Jefferies Financial Group cut their target price on Nextgen Healthcare from $14.00 to $11.50 and set a “hold” rating for the company in a research report on Wednesday, April 22nd. Finally, Robert W. Baird dropped their price objective on Nextgen Healthcare from $16.00 to $12.00 and set a “neutral” rating for the company in a research report on Thursday, May 7th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $12.46.
Nextgen Healthcare stock traded up $2.08 during midday trading on Friday, reaching $14.62. The stock had a trading volume of 1,035,280 shares, compared to its average volume of 254,836. The firm’s fifty day simple moving average is $10.96 and its 200-day simple moving average is $11.42. Nextgen Healthcare has a 1-year low of $5.10 and a 1-year high of $18.49. The stock has a market capitalization of $975.34 million, a P/E ratio of 162.44, a price-to-earnings-growth ratio of 5.85 and a beta of 0.99. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.82 and a current ratio of 1.82.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Two Sigma Advisers LP increased its holdings in Nextgen Healthcare by 145.6% during the first quarter. Two Sigma Advisers LP now owns 101,389 shares of the company’s stock worth $1,059,000 after buying an additional 60,100 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Nextgen Healthcare by 4.4% in the 1st quarter. Geode Capital Management LLC now owns 1,020,157 shares of the company’s stock worth $10,649,000 after purchasing an additional 42,563 shares during the period. Invesco Ltd. raised its holdings in shares of Nextgen Healthcare by 5.1% in the 1st quarter. Invesco Ltd. now owns 1,157,427 shares of the company’s stock worth $12,083,000 after purchasing an additional 56,047 shares during the period. Squarepoint Ops LLC bought a new stake in Nextgen Healthcare during the 1st quarter valued at $415,000. Finally, Goldman Sachs Group Inc. raised its holdings in Nextgen Healthcare by 14.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 306,615 shares of the company’s stock valued at $4,927,000 after acquiring an additional 39,172 shares during the period. Hedge funds and other institutional investors own 73.22% of the company’s stock.
About Nextgen Healthcare
NextGen Healthcare, Inc provides software, services, and analytics solutions to medical and dental group practices in the United States. The company's principal products include NextGen Enterprise EHR, which stores and maintains clinical patient information; and a workflow module, prescription management, automatic document and letter generation, patient education, referral tracking, interfaces to billing and lab systems, physician alerts and reminders, and reporting and data analysis tools.
Read More: Are sell-side analysts objective?
Receive News & Ratings for Nextgen Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nextgen Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.